Deghor 120 Mg Injection

Degarelix belongs to a class of medications known as gonadotropin-releasing hormone (GnRH) antagonists, which work by directly blocking GnRH receptors in the pituitary gland, leading to a rapid decrease in the production of testosterone. Since many prostate cancers rely on testosterone to grow, lowering its levels helps slow the progression of the disease and can help shrink existing tumors. Unlike some other hormone therapies that may cause an initial temporary surge in testosterone before levels drop, Degarelix works to reduce testosterone quickly without this initial flare, which can be an important consideration for certain patients. It is commonly used in the treatment of advanced or metastatic prostate cancer, often as part of a broader treatment strategy that may include other cancer therapies. The medication is administered by subcutaneous injection, typically starting with an initial dose followed by regular maintenance doses given on a monthly schedule. Regular monitoring, including testosterone and prostate-specific antigen (PSA) level checks, is an important part of treatment to help track the body's response and guide ongoing care. Many patients experience effective and sustained testosterone suppression, supporting meaningful control of their prostate cancer with consistent use. Ongoing follow-up with an oncologist or urologist helps ensure the treatment remains appropriate and effective over time. As with all hormone therapies for cancer treatment, Degarelix should be used under the close supervision of a healthcare provider experienced in prostate cancer care.